Buscador de publicaciones<< Volver

Núñez J, Sanchis J, Bodí V, Fonarow GC, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A

Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure.

Eur. Heart J.. 2010 Jul;31(14):1752-63, PMID: 20501480

Elevated brain natriuretic peptide (BNP) and tumour marker antigen carbohydrate 125 (CA125) levels have shown to be associated with higher risk for adverse outcomes in patients with acute heart failure (AHF). Nevertheless, no attempt has been made to explore the utility of combining these two biomarkers. We sought to assess whether CA125 adds prognostic value to BNP in predicting 6-month all-cause mortality in patients with AHF.


Una iniciativa de

Ministerio de Economía y Competitividad Fondo Europeo de Desarrollo Regional IMIM - Parc de Salut Mar